- Home
- CCIF vs SAVA Comparison
CCIF vs SAVA Comparison
Compare CCIF & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- SAVA
- Stock Information
- Founded
- CCIF 2011
- SAVA 1998
- Country
- CCIF United States
- SAVA United States
- Employees
- CCIF N/A
- SAVA N/A
- Industry
- CCIF Finance/Investors Services
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- SAVA Health Care
- Exchange
- CCIF Nasdaq
- SAVA Nasdaq
- Market Cap
- CCIF 121.4M
- SAVA 102.4M
- IPO Year
- CCIF N/A
- SAVA N/A
- Fundamental
- Price
- CCIF $5.39
- SAVA $4.30
- Analyst Decision
- CCIF
- SAVA Buy
- Analyst Count
- CCIF 0
- SAVA 2
- Target Price
- CCIF N/A
- SAVA $5.00
- AVG Volume (30 Days)
- CCIF 76.9K
- SAVA 6.3M
- Earning Date
- CCIF 01-01-0001
- SAVA 11-06-2025
- Dividend Yield
- CCIF 25.90%
- SAVA N/A
- EPS Growth
- CCIF N/A
- SAVA N/A
- EPS
- CCIF N/A
- SAVA N/A
- Revenue
- CCIF N/A
- SAVA N/A
- Revenue This Year
- CCIF N/A
- SAVA N/A
- Revenue Next Year
- CCIF N/A
- SAVA N/A
- P/E Ratio
- CCIF N/A
- SAVA N/A
- Revenue Growth
- CCIF N/A
- SAVA N/A
- 52 Week Low
- CCIF $7.43
- SAVA $1.15
- 52 Week High
- CCIF $10.16
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- CCIF 38.22
- SAVA 65.53
- Support Level
- CCIF $5.23
- SAVA $3.75
- Resistance Level
- CCIF $5.95
- SAVA $4.98
- Average True Range (ATR)
- CCIF 0.17
- SAVA 0.38
- MACD
- CCIF -0.02
- SAVA 0.07
- Stochastic Oscillator
- CCIF 18.83
- SAVA 67.69
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.